Dr. Harry Quigley is a preeminent authority in ophthalmology who serves as the A. Edward Maumenee Professor of Ophthalmology with the Glaucoma Center of Excellence at the Wilmer Eye Institute of Johns Hopkins University School of Medicine. Born in St. Louis, he graduated from Harvard College and earned his medical degree from Johns Hopkins Medical School where he was elected to Alpha Omega Alpha honor society. Following ophthalmic residency training at the Wilmer Institute, he completed a fellowship with Douglas Anderson at the renowned Bascom Palmer Eye Institute in Miami. Dr. Quigley has dedicated his career to advancing glaucoma research and clinical care, establishing himself as a global leader through his pioneering scientific contributions and clinical innovations.
Dr. Quigley's groundbreaking research has fundamentally transformed the early diagnosis and understanding of glaucoma, with his scientific publications representing the most cited works in ophthalmic literature over the past three decades. He pioneered instrumental techniques and diagnostic methods that significantly improved the identification of glaucoma damage at earlier stages, demonstrating for the first time the substantial degree of optic nerve damage that occurs before standard clinical detection. His extensive epidemiological studies across diverse American, African, Asian and Hispanic populations have provided critical insights into glaucoma progression rates and prevalence, establishing foundational knowledge for global treatment strategies. With over 400 peer-reviewed publications and an impressive H-factor of 118 reflecting more than 59,000 citations, his laboratory research has successfully demonstrated gene therapy approaches to protect retinal ganglion cells in experimental glaucoma models using primates, rats and mice.
As a founding member of the American Glaucoma Society where he served as Secretary for eight years, Dr. Quigley has played a pivotal role in shaping professional standards and advancing collaborative research in glaucoma care worldwide. His leadership extended to five-year terms as chief executive officer of the Association for Research in Vision and Ophthalmology and as Editor-in-Chief of Investigative Ophthalmology and Visual Science, where he influenced the direction of vision research globally. Honored with prestigious awards including the Friedenwald Award from ARVO, the Doyne Medal from the Oxford Ophthalmological Congress, and the Leslie Dana Medal from the St. Louis Society for the Blind, his contributions continue to inspire the next generation of ophthalmologists. Currently focusing on innovative gene and stem cell therapies for ophthalmic diseases, Dr. Quigley remains at the forefront of translational research, working to bridge laboratory discoveries with clinical applications that will transform patient care for generations to come.
